menu
    • menu
    [{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/ National Eye Institute"},{"orgOrder":0,"company":"Synedgen","sponsor":"JWMRP","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"MIIST305","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Synedgen","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Synedgen \/ JWMRP","highestDevelopmentStatusID":"14","companyTruncated":"Synedgen \/ JWMRP"},{"orgOrder":0,"company":"Synedgen","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"MIIST305","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Synedgen","amount2":0.12,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Synedgen \/ BARDA","highestDevelopmentStatusID":"14","companyTruncated":"Synedgen \/ BARDA"}]

    Find Clinical Drug Pipeline Developments & Deals by Synedgen

    Menu

    Synedgen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIIST305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : JWMRP

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Synedgen Wins $2.2M Award for Radiation Medical Countermeasure MIIST305

                            Details : The proceeds will be used for the development of company's lead therapeutic, MIIST305, an orally delivered, shelf-stable, gut-restricted therapy, as a prophylactic radiation countermeasure.

                            Brand Name : MIIST305

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 31, 2024

                            Lead Product(s) : MIIST305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : JWMRP

                            Deal Size : $2.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MIIST305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : BARDA

                            Deal Size : $119.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Synedgen Wins BARDA Contract for MIIST305 Radiation Syndrome Countermeasure

                            Details : The contract aims to develop Synedgen’s lead therapeutic, MIIST305, an oral, glycocalyx-targeted therapy, to address GI-ARS arising from acute exposure to ionizing radiation.

                            Brand Name : MIIST305

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 15, 2024

                            Lead Product(s) : MIIST305

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : BARDA

                            Deal Size : $119.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Synedgen

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery

                            Sponsor : National Eye Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injur...

                            Details : Synedgen has developed a new class of glycopolymers with the ability to suppress inflammation, reduce infection, and improve healing at mucosal surfaces. The additional funding provides resources to optimize down-selection to a lead molecule to advance i...

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 29, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery

                            Sponsor : National Eye Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth